Suggested remit: To appraise the clinical and cost effectiveness of avapritinib within its marketing authorisation for treating systemic mastocytosis.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Scoping commencing
Process STA Standard
ID number 3770

Provisional Schedule

Committee meeting: 1 06 August 2024

Project Team

Project lead Kate Moore

Email enquiries

External Assessment Group Newcastle NIHR TAR Team, Newcastle University


Companies sponsors Blueprint Medicines (Avapritinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Leukaemia Care
  The UK Mastocytosis support group
Professional groups Association of Cancer Physicians
  British Society for Allergy and Clinical Immunology
  British Society for Haematology
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Amarox – not participating
  Aspire Pharma – not participating
  Atnahs Pharma UK – not participating
  Aurobindo Pharma - Milpharm – not participating
  Cipla EU – not participating
  Dr. Reddy's Laboratories – not participating
  Esteve Pharmaceuticals – not participating
  Lipomed – not participating
  Novartis Pharmaceuticals (imatinib, midostaurin)
  Rivopharm UK – not participating
  Roche – not participating
  Rosemont Pharmaceuticals – not participating
  Sandoz – not participating
  Zentiva – not participating
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
19 July 2024 Avapritinib has not yet received regulatory approval, therefore the committee meeting discussion will be held in a private part 2 session only.
10 April 2024 The first committee meeting discussion has now been scheduled for 6 August 2024.
03 April 2024 The company, Blueprint Medicines, has provided their evidence submission which is being reviewed by the External Academic Group, Centre for Reviews and Dissemination and Centre for Health Economics – York. To ensure that the committee gets the best evidence package possible, this will no longer be discussed at the committee meeting on 2 July 2024. The second committee meeting discussion will be rearranged, and we will update all stakeholders with the new date in due course.
20 November 2023 Invitation to participate
18 July 2023 - 15 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3770
18 July 2023 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual